Timing and type of side effects differ greatly from chemotherapy
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Understudied Src Family Kinase may serve as a potential therapeutic target
Retired-protein strategy represents new approach to immunization
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Immunotherapy, PARP inhibitors and a targeted therapy
Multigene panel testing valuable regardless of age, cancer history
Newly discovered signaling axis opens therapeutic window
CDX-011 shows promise for triple negative disease